deformity was well (aged 69), and the other had died at 70 years from coronary artery disease. Out of 16 members of the next generation (including two with brachydactyly), 11 aged 45-54 years were screened for occult blood and by flexible sigmoidoscopy. One was found to have adenomatous polyps, and two metaplastic polyps; only one of these, however, had brachydactyly.
Appearances of brachydactyly of hands.
Comment
Features of the brachydactyly in this family were similar to those described by Vidal,4 and the variation in severity among family members has been reported. 5 The association of the condition with colorectal cancer may have been due to chance or may be a true syndrome, permitting identification of patients at risk for colorectal neoplasia. We should be interested to hear from others who may have observed the association.
In view of the high incidence of colorectal cancer in this family we propose to keep the family under periodic surveillance. 
Case reports
Case I-A 50-year-old man with grossoedema from the nephrotic syndrome was found to have impaired renal function (serum albumin concentration 15 g/l, creatinine concentration 475 mmol/l (5-4 mg/100 ml), glomerular filtration rate 33-4 ml/min/17 m2). Renal biopsy showed membranoproliferative glomerulonephritis. Frusemide was increased to 250 mg daily, and oedema persisted. Metolazone 2-5 mg daily was therefore added, and the oedema disappeared over two weeks. The figure shows the changes in urinary volume, electrolyte excretion, and body weight. 
Case report
A 63-year-old woman was started on benoxaprofen 600 mgs daily to relieve osteoarthritic pain of the hands and left knee. She had been treated with mefenamic acid and sulindac for several years, but these drugs were discontinued when benoxaprofen was started. Fourteen days later an erythematous papulopurpuric rash developed over the whole body surface, the thighs, forearms, and dorsum of hands being most severely affected. Bullae were present in the mouth and on the lips. She complained of severe pruritus. No other abnormalities were found on examination.
Erythrocyte sedimentation rate was 35 mm in the first hour; haemoglobin concentration 14-3 g/dl; and white cell count 7500 x 1091/ with a differential count of neutrophils 74 %, lymphocytes 9 %, monocytes 11 % and eosinophils 6 %. A coagulation screen was normal, as were uric acid, urea, and electrolyte concentrations, and results of liver function tests. Electrocardiography and chest x-ray films were normal. A test for antinuclear factor was negative. Skin biopsy specimens were consistent with erythema multiforme, showing perivascular lymphocytic infiltrate in the dermis with spongiosis and lymphocytic infiltration of the epidermis. Direct immunofluorescence tests with labelled antihuman immunoglobulin A and G and C3 were negative. Benoxaprofen was stopped on admission and the rash subsided over the course of 14 days. Profuse desquamation occurred, particularly on the palms of the hands. At no stage did the rash resemble a photoallergic or phototoxic drug rash.
Comment
The Stevens-Johnson syndrome is a potentially lethal condition that is often precipitated by drug treatment, sulphonamides being the drugs most commonly implicated.2 The association of this syndrome with treatment with benoxaprofen is important, especially in view of the enthusiastic press reviews3 4 which greeted the launch of the drug. 
Patients, methods, and results
Patients diagnosed as suffering from either common or classical migraine as defined by the World Federation Neurology Research Group on Migraine and Headache were invited to participate in the trial. Those with coexistent medical or psychiatric complaints were excluded. A double-blind procedure was followed with patients receiving placebo, clonidine 0-05 mg three times daily, or indoramin 20 mg three times daily for the first six months. Patients who had received clonidine during this time with no response were given indoramin and those who had been taking placebo without improvement were randomly allocated to clonidine or indoramin for a subsequent six months. Patients kept diary records and were reviewed monthly.
Eighteen men participated in the trial, of whom I1 received indoramin. Four men spontaneously complained of failure of ejaculation while receiving indoramin. Of the remaining seven, five were available for review, the other two defaulting from follow-up. These five men were asked specifically whether they had noted any change in sexual function, and two described failure of ejaculation. The ages of the nine patients reviewed ranged from 19 to 47 years (mean 37 years). Most of those affected had taken indoramin for at least two weeks before noting the disturbance, although in one man it had occurred on the day after starting treatment. All six affected patients described normal erections and had experienced orgasms despite total lack of ejaculation. None had noted this effect before starting indoramin, and it did not occur after the drug was stopped. No patients receiving placebo or clonidine complained of change in sexual function.
Comment
Ejaculation is a complex process affecting sympathetic, parasympathetic, and somatic pathways. Sympathetic nerves stimulate the delivery of semen to the urethra by the vas deferens, seminal vesicles, and prostate and prevent retrograde ejaculation by stimulating the internal urinary sphincter. Thoracolumbar sympathectomy from T12 to L3 abolishes seminal emission without disturbing erectile potency or the sensation of orgasm: the experience of "dry sex" as described by Kedia and Markland.4 They also reported the same
